Food for thought: formulating away the food effect - a PEARRL review by O'Shea, Joseph P. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Food for thought: formulating away the food effect - a PEARRL review
Author(s) O'Shea, Joseph P.; Holm, René; O'Driscoll, Caitríona M.; Griffin,
Brendan T.
Publication date 2018-06-28
Original citation O'Shea, J. P., Holm, R., O'Driscoll, C. M. and Griffin, B. T. 'Food for
thought: formulating away the food effect – a PEARRL review', Journal
of Pharmacy and Pharmacology, 71(4), pp.510-535 doi:
10.1111/jphp.12957
Type of publication Article (peer-reviewed)
Link to publisher's
version
https://onlinelibrary.wiley.com/doi/abs/10.1111/jphp.12957
http://dx.doi.org/10.1111/jphp.12957
Access to the full text of the published version may require a
subscription.
Rights © 2018 Royal Pharmaceutical Society. This is the peer reviewed
version of the following article: O'Shea, J. P., Holm, R., O'Driscoll,
C. M. and Griffin, B. T. (2018), Food for thought: formulating away
the food effect – a PEARRL review. J Pharm Pharmacol., which has
been published in final form at https://doi.org/10.1111/jphp.12957.
This article may be used for non-commercial purposes in
accordance with Wiley Terms and Conditions for Self-Archiving.
Item downloaded
from
http://hdl.handle.net/10468/7108
Downloaded on 2019-12-02T14:23:00Z
Page 1 
 
Food for thought: formulating away the 1 
food effect - a PEARRL Review 2 
Joseph P. O’Shea1, René Holm2, Caitriona M. O’Driscoll1, Brendan T. 3 
Griffin1,*  4 
1 School of Pharmacy, University College Cork; Ireland 5 
2Drug Product Development, Janssen Research and Development, Johnson & 6 
Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium 7 
*Correspondence to: 8 
Abstract 9 
Objectives: Co-ingestion of oral dosage forms with meals can cause substantial changes in the rate 10 
and extent of drug absorption relative to the fasted state. Food mediated effects on bioavailability 11 
can have significant consequences in drug development, regulatory and clinical settings. To date the 12 
primary focus of research and analysis has focused on the ability to mechanistically understand the 13 
causes and predict the occurrence of these effects.  14 
Key findings: The current review describes the mechanisms underpinning the occurrence of food 15 
effects, sheds new insights on the relative frequency that these effects occur in new medicinal 16 
products and describes the various methods by which they can be overcome. Analysis of new oral 17 
medicines licensed by either the EMA or FDA since 2010 revealed that over 40% of new medicinal 18 
products display significant food effects.  Due to altered bioavailability, these medicines are often 19 
required to be dosed, rather restrictively, in either the fed or the fasted state, which can hinder 20 
clinical usefulness.  21 
Conclusions: There are clinical and commercial advantages to predicting the presence of food effects 22 
early in the drug development process, in order to mitigate this risk of variable food effect 23 
bioavailability. Formulation approaches aimed at reducing variable food-dependent bioavailability, 24 
through the use of bio-enabling formulations, are an essential tool in addressing this challenge and 25 
the latest state-of-the-art in this field are summarised here  26 
 27 
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Introduction 31 
The concomitant administration of oral dosage forms with food can have a significant impact on drug 32 
pharmacokinetics and bioavailability relative to the fasted state. With oral drug delivery continuing to 33 
be the method of choice for drug administration, understanding the effects food has on the 34 
biopharmaceutical aspects of drug delivery is key to the drug development process as well as the 35 
effective and rational use of medicines in the clinical setting [1, 2]. Oral medicines are generally required 36 
to be repeatedly administered, often chronically and in multiple daily dosings, so it is inevitable that 37 
drugs will be administered in different prandial states. The understanding of the effects food has on 38 
pharmacokinetics is consequently a critical factor in assessing the clinical potential of new medicines 39 
and designing a food effect resistant formulation early in drug development can both provide a 40 
commercial advantage and prevent costly reformulation later in the product lifecycle [1, 3]. 41 
It is just over 40 years since the publication of the first major review focusing on the manner by 42 
which food affects drug absorption [4], and the topic has been subject to extensive research and 43 
review in the interim [5-9, 3, 10, 11]. Despite the abundance of studies examining the predictability, 44 
mechanistic understanding, and ability to overcome the effects of food on bioavailability, a universal 45 
approach to quantitatively predict food effect does not exist, nor is it a likely prospect. Significant 46 
progress has, however, been made in identifying potential drug candidates and drug products that 47 
display food effect bioavailability, understanding the mechanisms by which food effects occurs and 48 
developing formulations to overcome this effect.  49 
While there has been comprehensive review and analysis of the mechanisms underlying the food 50 
effect, and more recently of current approaches to predict food effect (Pentafragka et al., this 51 
issue)[12], to date there has been limited analysis of the relative abundance of medicines which 52 
display food effect and the systematic approaches utilised to eliminate food mediated changes in 53 
bioavailability. The aims of the current review are, therefore, to briefly summarise the main causes 54 
of food mediated changes in bioavailability, discuss the clinical and regulatory impact with regard to 55 
the types of and abundance of preparations which display significant food effects and to describe 56 
the various formulation approaches currently implemented to overcome the food effect. To our 57 
knowledge this is the first review to focus primarily on the use of enabling formulations to overcome 58 
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food effects on bioavailability in clinical and pre-clinical studies, while it also provides an updated 59 
compilation of recently licensed medicines which demonstrate significant food effect.  60 
  61 
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Food Effects; causes and clinical consequences 62 
What is a food-effect? 63 
In its simplest terms, food effects on drug absorption are observed when the rate and/or extent of 64 
drug bioavailability is altered when a drug or drug product is administered in fed state, compared to 65 
the fasted state. The clinical effects and significance of food effects on absorption are generally 66 
assessed with regard to the rate and extent of bioavailability – as measured by peak plasma 67 
concentrations (Cmax), time to peak plasma concentration (Tmax) and the total extent of bioavailability 68 
(area under the curve; AUC) [1]. Welling classified food drug interactions into five categories causing 69 
[5]; 70 
• Reduced extent of bioavailability  71 
• Delayed rate of absorption 72 
• Increased extent of bioavailability  73 
• Accelerated rate of absorption 74 
• No effect 75 
With regard to clinical significance, the most crucial aspect of food effect is generally considered to 76 
be the extent of bioavailability change, and the terms ‘positive food effect’ and ‘negative food effect’ 77 
have been coined to describe either an increase or decrease in the overall extent of bioavailability, 78 
respectively[1]. While some variation in bioavailability is tolerated, larger deviations in the fed, 79 
relative to the fasted state can have clinical implications. It is, thus, necessary to have some guidance 80 
on defining what exactly constitutes a significant food effect. Accordingly, the FDA have provided 81 
guidelines on how to design clinical trials to investigate food effects, recommending dosing in both 82 
fasted and fed states. The FDA guidance defines that a food-effect is established if the 90% 83 
confidence intervals for the ratio of population geometric means, based on log-transformed data, 84 
for either AUC0→∞ or Cmax fall outside the 80-125% bioequivalence limits relative to the reference, i.e. 85 
the same formulation administered in the fasted stated [13]. The fed state represents dosing post 86 
ingestion of a high fat, FDA standard breakfast, containing 800 – 1000 kcal with approximately 50% 87 
of total calories coming from fat, to maximise potential for demonstrating a food effect [13].  88 
Figure 1 illustrates the key steps in drug absorption and bioavailability and indicates how food 89 
influences these processes, while the underlying mechanisms of these processes are described in 90 
subsequent sections of this review. 91 
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 92 
Figure 1 Schematic diagram of critical steps in drug absorption and influence of food and food components; FPM: first 93 
pass metabolism 94 
Mechanisms underlying the food effect 95 
Drug absorption via the oral route is a function of the interplay of various complex 96 
biopharmaceutical processes, namely (i) drug molecular and physicochemical properties, (ii) 97 
formulation characteristics, (iii) the physiological changes of the gastrointestinal tract induced in the 98 
fed state and (iv) the physical chemical changes in the composition of the gastrointestinal fluid [1]. 99 
The Biopharmaceutical Classification System (BCS) and Biopharmaceutical Drug Disposition 100 
Classification system (BDDCS) provide a useful predictor of potential food effects based on drug 101 
physicochemical properties, as summarised in figure 2 [14, 15]. The anticipated effects are predicted by 102 
the most likely limiting factor for bioavailability, namely solubility or dissolution for BCS/BDDCS class 103 
II compounds, permeability for class III compounds, or a combination thereof for BCS class IV 104 
compounds. An overall delay in Tmax and reduced Cmax for highly bioavailable compounds can be 105 
associated with a delayed gastric emptying [16]. While this tool does not capture all the potential 106 
effects of food, it is the most widely utilised simple tool to predict food effect behaviour, and is 107 
estimated to be accurate in approximately 70% of cases [17]. 108 
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 109 
Figure 2 Predicted effect of high fat meals by BCS/BDDCS class. Adapted from Custodio et al. (2008) 110 
 111 
Drug absorption is inherently variable, owing to both inter- and intra-individual variability in the 112 
physiology of the GIT. When considering the gut physiology McConnell et al. have stated that there 113 
is ‘no such thing as an average person’[18], and despite regulatory guidance, equally there is no such 114 
thing as a standard meal [13]. The purpose of FDA guidance is to provide a standard for bioavailability 115 
and bioequivalence studies, where the likelihood of observing a food effect is maximised. However, 116 
this is not always reflective of the fed state for patients, which adds further to the variability and 117 
complexity of absorption and drug product performance.  118 
In the fed state the physicochemical composition of the gastrointestinal fluid, including its volume, 119 
pH, osmolality, surface tension, hydrodynamics and overall composition change. These changes have 120 
been extensively reviewed by Pentafragka et al. in the current issue[12]. The reader is directed here for 121 
greater detail, specifically with regard to the intraluminal environment after intake of meals similar in 122 
composition to that suggested by the FDA and EMA for food effect and fed state bioequivalence 123 
studies i.e. a high-fat, high-caloric meal [13, 19]. There are a number of additional factors that may 124 
influence GIT absorption from oral dosage forms and the most pertinent aspects are described below, 125 
and summarised in figure 3. 126 
  127 
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Food induced changes on drug absorption 128 
Gastrointestinal fluid composition 129 
With regard to drug absorption of immediate release dosage forms, it is the characteristics of the 130 
stomach and upper intestine which are generally most crucial for drug absorption. Relative to the 131 
fasted state, the most pertinent changes in the intraluminal environment include the increase in 132 
gastric pH to 5 or higher, along with a corresponding increase in buffer capacity[20-22]. The intragastric 133 
fluid volume also increases significantly in the fed state, with increases in the presence of dietary lipids 134 
and their digestion products along with increased viscosity of the luminal contents[23-26]. The most 135 
significant changes in the small intestinal luminal fluid composition is the increase in bile salt 136 
concentrations and the presence of lipid digestion products[27, 24, 28-30]. The extensive absorption in the 137 
small intestine means that despite the fluid ingested with a meal and significant gastrointestinal 138 
secretions, the overall volume of fluid in the small intestine actually decreases in the fed state[23, 25]. 139 
Gastrointestinal motility and its impact on transit time of dosage forms 140 
The interplay between GIT motility and intestinal transit of dosage forms can be complex and 141 
affected by numerous factors. In the fasted state, emptying of liquid formulations will occur quite 142 
rapidly, whereas emptying of solids can be delayed by up to 2 hours [31-34, 10]. In the fed state, liquids 143 
and smaller particles (<3-4mm) will empty with food, at a rate controlled by the caloric density of 144 
the food, but which is invariably slower than the fasted state [31, 35]. Larger particles (>7mm) can be 145 
retained in the fed state, displaying a significant lag time [36]. Fadda et al. have estimated the gastric 146 
transit of a non-disintegrating tablet in the fasted, fed and pre-fed state with a median (IQR) gastric 147 
emptying time of 37 (19-74) minutes, 149 (119-171) minutes and 39 (25-169) minutes in each state, 148 
respectively [37].  Small intestinal transit time appears to be remarkably independent of fed state, and 149 
mean values are consistently reported to be 3-4 hours [38, 37]. However, this mean value masks 150 
considerable inter- and intra-individual variation.  151 
Metabolism and transporter effects 152 
Both dietary components, including monoglycerides, and bile salts have been shown to have an 153 
inhibitory effect on both uptake and efflux transporters in vitro, regularly leading to suggestions that 154 
high fat meals may lead to inhibition of intestinal enzymes, as well as efflux and uptake 155 
transporters[16, 39]. While many enteric enzymes are responsible for drug metabolism, it is the 156 
cytochrome P450 (CYP450) family, in particular the CYP3A and CYP2C subfamilies, which are most 157 
widely implicated in such interactions as they are the most abundant family and play a crucial role in 158 
bioavailability of a wide range of molecules [40, 39].The most commonly implicated transporters are 159 
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the organic anion transporter polypeptides (OATP) and P-glycoprotein (p-GP) efflux transporters [41, 160 
42, 16, 43, 39]. However, despite the widely cited assertion that food, generally, inhibits intestinal 161 
transporter and enzyme function, to date the clinically important interactions of note regarding 162 
enzyme and/or transporter inhibition involve specific food components. Most notable among these 163 
is the inhibition of CYP450 enzymes by grapefruit juice, while other foods rich in phytochemicals, 164 
such as fruits, herbs and red wine have also been implicated [42, 44, 16, 39]. This constitutes a specific, 165 
and well characterised phenomenon involving an individual food component, which is not what is 166 
typically considered when discussing food effect, which usually refers to the effects of meals 167 
generally rather than the impact of individual components.  168 
 169 
 170 
 171 
 172 
Figure 3 Summary of human physiological changes in the fed state (adapted from Varum et al. [3]) 173 
  174 
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Mechanisms of food effect 175 
As has been described above, food has a complex and significant effect on the physiology of the 176 
gastrointestinal tract and the physicochemical properties of gastrointestinal fluid, which in turn can 177 
have a significant effect on drug absorption. These effects are dependent on both the 178 
physicochemical properties of the drug, principally solubility, pKa and LogP/logD, and formulation 179 
characteristics, including release and disintegration of solid dosage forms [45, 46, 8]. For the purposes of 180 
this review, the focus will predominantly be on immediate release and bio-enabling formulations, 181 
the mechanisms by which food causes these changes in bioavailability are discussed here and 182 
summarised in table 1. The effect of food on modified release dosage forms can be significantly 183 
different to that of immediate release preparations, notably with regard to disintegration and 184 
release and the potential for dose dumping. The effects of food on modified release formulations 185 
have recently been reviewed by Varum et al. (2013)[3], Yasuji et al. (2012)[9] and Abuhelwa et al. 186 
(2017)[10].  187 
Positive food effects 188 
The principal cause of positive food effects is the increase in dissolution and solubilisation of poorly 189 
water soluble drugs (PWSD) in the fed state. The release of bile salts and the presence of exogenous 190 
solubilising species, such as ingested lipids and their digestion products serve to enhance solubilising 191 
capacity of gastrointestinal fluid [28, 47, 30, 48-50]. For drugs which are dissolution rate, rather than 192 
solubility limited, the increased gastric residence time also can improve bioavailability, while the 193 
increase in gastric pH may result in improved solubility and dissolution of weak acids. In practical 194 
terms, it is difficult to isolate the impact of any one of these factors, which work synergistically to 195 
increase solubility and dissolution of PWSD. 196 
The inhibition of intestinal transporters can play a role in enhancing bioavailability of certain drugs. 197 
Wu and Benet have demonstrated that for BCS class II compounds efflux transporters predominate, 198 
and that for these compounds transporter inhibition is likely to improve bioavailability [51, 15, 16, 52]. 199 
Reduction in first pass metabolism in the fed state can also lead to increases in bioavailability and 200 
this can occur through numerous mechanisms including altered blood flow, increased lymphatic 201 
uptake and reduced enteric metabolism. Food intake is associated with an increase in splanchnic 202 
blood flow by as much as 60% depending on the volume and nature of the meal. This allows drug to 203 
bypass the liver, while the increase in hepatic blood flow may also reduce the first pass effect for 204 
drugs which display low to moderate clearance [53-55].  Co-administering lipophilic drugs with food 205 
allows efficient absorption of these molecules with dietary lipids, via lipid absorption pathways, 206 
while particularly lipophilic drugs (logP>5) can also show significant lymphatic uptake [56, 30, 57]. This 207 
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can increase the systemic absorption by both increasing the fraction escaping the gastrointestinal 208 
lumen and reducing the first pass effect.  209 
The inhibitory effect of meal components on CYP3A4 is also a significant contributor to the reduction 210 
of enteric drug metabolism and increased bioavailability in the fed state. Inhibition of CYP3A 211 
metabolism by grapefruit juice has been widely associated with increases in bioavailability and 212 
subsequent increases in adverse events for a wide range of pharmacologically diverse compounds [40, 213 
16]. While  both dietary monoglycerides and bile salts have been demonstrated to have an inhibitory 214 
effect on enzymatic activity in vitro, and it has regularly been asserted that this inhibition leads to 215 
clinically relevant enzyme inhibition by high fat meals such interactions have not yet been 216 
extensively characterised in vivo [42, 16, 39, 3].  217 
Negative food effects 218 
Negative food effects encompass both reduced and delayed drug absorption. With regard to delayed 219 
absorption in the fed state, this often occurs for immediate release preparations without a 220 
corresponding reduction in overall bioavailability. The main mechanism by which this occurs is 221 
delayed gastric transit in the fed state. This manifests itself as a prolonged Tmax, which may or may 222 
not be accompanied by a reduction in Cmax or a significant lag time. For medicines which are 223 
chronically dosed and where overall exposure, rather than peak plasma levels, mediate 224 
pharmacodynamic action, this is unlikely to result in clinically meaningful effects [7]. 225 
Decreased absorption in the fed state results in a reduction in AUC, along with a reduction in Cmax, 226 
and can lead to sub-therapeutic plasma levels and loss of efficacy. The most common causes of 227 
reduced bioavailability in the fed state are direct physicochemical interactions between drugs, or 228 
drug products, and food. One potential cause of this effect is the reduced diffusivity of drug in the 229 
viscous postprandial upper GIT. The increased viscosity can result in either inhibition of 230 
disintegration of a dosage form, preventing drug release, or hindering diffusion of drug to the 231 
absorptive membranes of the GIT [58-61]. This can be problematic for poorly permeable drugs, 232 
particularly those with narrow absorption windows, as by the time viscosity has reduced in the distal 233 
gut, the absorption window has been transited and absorption will be reduced [62-64]. A second direct 234 
mechanism by which food can hinder drug absorption is by binding of drug with food components 235 
[65, 7]. This is prevalent in the case of polyvalent cations, which are abundant in dairy products [66-68, 7, 236 
69]. 237 
Physiological factors can also play a role in negative food effects, especially in the case of drugs 238 
displaying instability and possibly acid lability in the GIT. Prolonged gastric residence can result in 239 
increased degradation of these molecules, though in the case of acid labile drugs the effect may be 240 
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somewhat mitigated by the increase in gastric pH [70]. Food can also result in alterations in 241 
absorption through altering both passive permeability and active transport. The presence of 242 
increased lipids and bile salts in the fed state can result in micellar entrapment, with the consequent 243 
decrease in free drug causing a reduction in permeability [45, 71-73, 49]. While for poorly soluble drugs, 244 
this is generally more than compensated for by increases in solubility, highly soluble and poorly 245 
permeable compounds may display reduced absorption in this case.  246 
The inhibition of uptake transporters may also result in negative food effects. For poorly permeable 247 
drugs, the inhibition of these transporters may result in a reduction in absorption, as these 248 
compounds are often reliant on the action of uptake transporters. The general inhibition of 249 
intestinal transporters observed in the fed state is therefore likely to reduce the bioavailability of 250 
BCS class III compounds. Care is needed, however, when applying this rule of thumb, as class III 251 
compounds may be candidates for both uptake and efflux transporters and the relative inhibition of 252 
either uptake or efflux transporters, or the extent to which a specific molecule will be a substrate for 253 
each particular class can determine the overall effect of bioavailability [16]. Fexofenadine is a BCS 254 
class III compound which displays a negative food effect, as predicted by its BDDCS class. 255 
Fexofenadine is a substrate for both OATP uptake transporters and P-gp efflux transporters. In the 256 
fed state, principally when taken with fruit juices, the inhibition of OATP transporters predominates 257 
and absorption is decreased [74-77]. Fruit juice related inhibition of OATP uptake has also been 258 
implicated in a reduction in AUC for other drugs, including aliskiren and celiprolol[74, 78-80]. The 259 
inhibition of PAT1 has been suggested as a possible reason for the reduced rate of absorption of 260 
vigabatrin, though this is most likely due to a reduction in the rate of gastric emptying [81, 82].  261 
The events described here are summarised and examples of drugs affected by the various 262 
mechanisms are provided in table 1.  263 
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 264 
Table 1 Summary of physiological mechanisms and biopharmaceutical aspects underpinning the food effect 265 
Physiological mechanism Biopharmaceutical 
aspects 
Effect on Drug 
exposure 
Example(s) 
Increased pH in stomach Solubility and 
dissolution of 
ionisable compounds 
can be altered 
Increases AUC and 
Cmax for weak 
acids 
Decreases AUC and 
Cmax for weak 
bases 
Cefuroxime 
 
Dipyridamole, 
indinavir 
Increased concentration of 
solubilising species e.g. bile 
salts, lipid digestion products 
Solubilisation of 
poorly water soluble 
drugs increases 
Increases AUC and 
Cmax 
Fenofibrate 
Alectinib 
Danazol 
Increased splanchnic blood 
flow 
Saturation of liver 
enzymes and 
avoidance of FPM 
Increases AUC and 
Cmax 
Propranolol 
Tacrine 
Dronedarone 
Inhibition of gastrointestinal 
Cytochrome P450 – e.g. with 
Grapefruit juice 
Fraction of drug 
escaping gut 
metabolism increases 
Increases AUC and 
Cmax 
Felodipine 
Ciclosporin 
Atorvastatin 
Inhibition of intestinal 
absorptive and efflux 
transporters 
Fraction of drug 
subject to either 
absorptive or efflux 
transport is reduced 
Increases AUC and 
Cmax for drugs 
subject to efflux 
Decreases AUC and 
Cmax for drugs 
which require 
uptake transporters 
Ganciclovir 
 
 
Fexofenadine 
Talinolol 
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Delayed gastric emptying Presence of food in 
stomach delays transit 
of drug to small 
intestine 
Increases Tmax, can 
decrease Cmax, may 
cause Tlag 
Widespread 
NSAIDs 
Paracetamol 
 
Increase in viscosity of 
intestinal fluid 
Reduction in water 
diffusivity, increase in 
luminal viscosity, 
slower water 
penetration of dosage 
form, increased 
disintegration time 
Increases Tmax, may 
reduce Cmax and F, 
may cause Tlag 
Chlorothiazide, 
Metformin 
 
  266 
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Clinical significance 267 
Most medicines contain instructions to take the medication with a glass of water and often gives 268 
specific instructions to either take with food, occasionally specifying the size or content of the meal, 269 
or in the fasted state. These recommendations are generally designed either to improve safety and 270 
tolerability or to maximise the oral absorption. For example, it is recommended to take Fampyra® 271 
(fampridine) without food in order to reduce the risk of adverse events as ‘there is a clear 272 
relationship between Cmax and dose related adverse reactions’, and taking Fampyra® with food is 273 
associated a 15-23% increase in Cmax[83]. Similarly, the reduction in Cmax of trifluridine observed in the 274 
fed state when taking Lonsurf® may prevent a reduction in neutrophils[84].  Conversely, it is 275 
recommended to take both Orkambi® and Kalydeco® with fat containing meals to improve 276 
bioavailability and clinical efficacy, as there a 2-4 fold increase in exposure of both lumacaftor and 277 
ivacaftor are anticipated when these medicines are administered with fat containing food[85, 86]. 278 
Other considerations may include the slower rate of absorption widely observed in the fed state. 279 
While there is no overall effect on bioavailability, the orexin receptor antagonist suvorexant 280 
(Belsomra®) should not be administered with or soon after a meal, as this may delay sleep onset[87]. 281 
However, occasionally there may be contradictory advice or a lack of evidence for justifying these 282 
recommendations and occasionally the justification can seem counter-intuitive. For example, it is 283 
often recommended to take non-steroidal anti-inflammatory drugs (NSAIDs) with food, with the 284 
justification that this can reduce the incidence of gastric side effects, though the extent to which this 285 
is effective is questionable. Rainsford and Bjarnason (2011) have stated that ‘there are no specifically 286 
claimed benefits from these recommendations and their origins have not been made clear’, while 287 
Moore et al. (2015) have said that the evidence that taking NSAIDs with food achieves its objectives 288 
is non-existent[88, 89]. Taking NSAIDs with food has been shown to delay Tmax and reduce Cmax with no 289 
overall effect on bioavailability. Considering that early, high plasma drug concentrations produce 290 
better and longer lasting analgesia in acute pain, and reduce the frequency of re-medication, it 291 
appears that the recommendation to take NSAIDs with food is misguided [90, 89].  292 
Another implication of significant food effect is the potential implications for the clinically efficacy. 293 
Ziprasidone (Geodon®) is an orally active atypical antipsychotic used in the treatment of bipolar 294 
affective disorder, which displays non-linear pharmacokinetics in the fasted state, while its 295 
absorption is approximately doubled by taking with a meal containing at least 500 kcal. Despite the 296 
significant food effect observed and label instructions to take Geodon® with food, about 40% of 297 
patients do not consistently take the medication with sufficient food and physicians have suggested 298 
that it is less effective in patients displaying poor compliance to the dose instructions [91].  299 
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The impact of food on drug bioavailability is pertinent for new molecularly targeted therapies in 300 
oncology, particularly in the case of the kinase inhibitors [92]. While FDA drug label instructions are 301 
generally designed to maximise the bioavailability of the drug, there is a distinct reversal of this 302 
situation for oncological preparations, where there is a noticeable trend towards label instructions 303 
to take medication in the fasted state despite significant increases in bioavailability in the fed state 304 
[93]. This appears to run contrary to established understanding of basic biopharmaceutical principles, 305 
which would suggest that bioavailability may be enhanced, while variability can be reduced by co-306 
administering these drugs in the fed state [94]. This has resulted in suggestions of wastefulness, with 307 
some clinicians proposing that by ignoring the label recommendations and administering some of 308 
these antineoplastic agents with food that significant savings may be made such as $1,700 per 309 
month in the case of lapatinib or $3,750 per month in the case of abiraterone acetate [95, 96]. While 310 
the case for taking these medicines with food in an off-label manner seems to stand to reason, other 311 
factors are important and warrant consideration, not least of which is conditions under which the 312 
drug product is licensed. While food effect studies are most often carried out as single dose studies 313 
in healthy subjects, the pivotal phase 3 clinical studies, which establish safety and efficacy in 314 
patients, may have been initiated in different prandial conditions, leading to a licensed dosing 315 
recommendation which reflects that of the relevant clinical study [97, 98]. Dosing in differing prandial 316 
conditions runs to that recommended in the drug product label constitutes off-label administration, 317 
and risks administration under conditions which have not definitively been demonstrated as safe 318 
and effective, while patient adherence to label recommendations is a major concern for oncologists 319 
and their ability to manage dosage regimens [99, 98]. The role of inter- and intra-individual variation, 320 
regarding  meal composition and timing of taking medication with food is also a pertinent 321 
consideration [100, 98]. For example, while lapatinib exposure can be increased greater than four-fold 322 
when taken with a high fat meal relative to the fasted state, this increase is only two fold when 323 
administered with a low fat meal. Considering the high fat and caloric content of the FDA high fat 324 
breakfast, it is not realistic to replicate the controlled environment of a food effect trial in the clinical 325 
setting, and variations in meal composition from day to day can result in large intra-individual 326 
variation [101, 102]. In these cases it may be more reproducible, easily understood and easier to 327 
promote patient and clinician adherence where medicines are dosed in the fasted state [97].  328 
In cases where a specific type of meal is explicitly detailed, this can add further to the complexity. 329 
With regard to the multi-kinase inhibitor regorafenib (Stivarga®), the type of meal is particularly 330 
important, not only for the magnitude but, in fact, for the direction of the food effect. A significant 331 
increase in bioavailability was observed with a low fat breakfast, while a high fat meal causes a 332 
reduction in bioavailability with the resultant recommendation to ‘take Stivarga® with food (a low-333 
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fat breakfast)’ [84]. Specifying a particular meal further adds to the risk associated with clinical use of 334 
medicines which display significant food mediated alterations in bioavailability, and risks reducing 335 
compliance with dosage regimens. It must be acknowledged that, with regard to oncological 336 
products, there may be specific challenges for fed state administration when considering the side 337 
effect profiles, such as nausea and vomiting, along with reduced appetite of patients undergoing 338 
certain chemotherapeutic regimens. While the debate continues as to whether these medications 339 
are best administered in the fed or fasted state, one thing which is abundantly clear is that a method 340 
of delivering these drugs in a reproducible, bio-enhanced manner, independent of prandial state 341 
would be advantageous. 342 
Overall, establishing the clinical implications of food effect can be difficult, from the point of view of 343 
development scientists, clinicians and, indeed, regulators. The FDA bioequivalence criteria are 344 
deliberately conservative, ensuring maximal opportunity to observe a food effect, and do not take 345 
into account the variability and therapeutic window of the drug being assessed. A modest increase 346 
or decrease in bioavailability in the fed state will mean that bioequivalence is not demonstrated, 347 
however, if this drug displays large variability in bioavailability and/or possesses a wide therapeutic 348 
window, a modest change in variability, such as the 30% increase in exposure observed for gefitinib, 349 
is unlikely to be clinically significant [98]. This is notable among some of the recently licensed 350 
polymerase and protease inhibitors licensed in the treatment of the hepatitis C virus (HCV), in both 351 
individual and combination products, including Zepatier® (elbasvir and grazoprevir), Epclusa® 352 
(sofosbuvir and velpatasvir) and Daklinza® (daclatasvir). These products all display modest variations 353 
in bioavailability in the fed compared to the fasted state, though these minor changes are not 354 
deemed clinically relevant, allowing dosing independent of meal intake (table 2).  355 
Another factor to consider is that while food effect studies are most often single dose studies, often 356 
this effect is lessened with multiple dosing, where variability in the patient population 357 
pharmacokinetics and the therapeutic window of the drug in question are important considerations  358 
Such an example is that of Syndros® (dronabinol) where, despite a 2.5 fold, increase in exposure in a 359 
single dose fed state pharmacokinetic study, only the first dose is recommended to be taken with 360 
food, with subsequent dosing taken without regard to meals (table 2). 361 
Yan et al. have recently identified numerous cases where there are label differences with regard to 362 
food effect between the US product information (PI) and European summary of product 363 
characteristics (SPC) [11]. This demonstrates the difficulties in interpretation of food effect data, 364 
which may be subjective and not entirely dependent on pharmacokinetic considerations, but also on 365 
the clinical pharmacodynamic response. It is also interesting to note that there does not appear to 366 
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be a consistent trend in these differences and of the products they identified, two-thirds displayed 367 
significant pharmacokinetic food effects. In the case of the anticoagulant Xarelto® (rivaroxaban), the 368 
clinical recommendation in fact varies between product strength, where the 10mg and 15mg 369 
preparations can be taken with or without a meal, while the 20mg strength should be taken with a 370 
meal[103]. It is easy to envisage difficulties for clinicians in advising patients where dosing instructions 371 
vary for the same products between jurisdictions, but also between dose strengths. 372 
Table 2 provides a summary of the food effects of newly licensed drugs or formulations approved in 373 
the US and/or EU over the last seven years which have, demonstrated significant food effect, or have 374 
been designated with a label restriction with regard to the administration of drug with regard to 375 
food. A food effect was considered significant if the ratio of AUC and/or Cmax in the fed and fasted 376 
states fell outside 80-125%. We have also included products with a specific label claim regarding 377 
dosing with food. In cases where it was stated that a product showed no change or a non-significant 378 
change in either AUC or Cmax in the fed or fasted state, but no values or ratios were obtained, a value 379 
of 1 was assigned. 380 
Interestingly, our estimates have suggested that approximately 40% (67 of 157 products identified; 381 
42.68%) of medicines licensed by the EMA and FDA since January 1st 2010 display a significant food 382 
effect or have been licensed with a label restriction with regard to dosing with or without food. 383 
Included in this analysis were new chemical entities, new combination products and previously 384 
marketed active pharmaceutical ingredients which have been reformulated. Excluded from our 385 
analysis were generic medicines/ abbreviated new drug applications (ANDAs), parenteral, topical, 386 
transdermal and other non-oral preparations (including buccal and sublingual preparations and 387 
orally disintegrating tablets), extended/ controlled release preparations and oral medicines designed 388 
for local administration within the GIT, i.e. those not subject to appreciable levels of absorption. In a 389 
competitive market place, the ability to take a medicine without regard to the timing of meals 390 
presents a clear commercial advantage for developing dosage forms that can be administered 391 
independent of food [104].  392 
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Table 2 Recently licenced medicines displaying significant food effect and/or food specific dosage instructions  393 
Data obtained from FDA Drug Label (from Drugs@FDA database) or European Summary of Pharmaceutical Characteristics (SPC) unless otherwise stated 394 
Year 
licensed Drug Name 
Commercial 
Name 
Clinical Recommendation regarding 
timing of food Food Effect 
AUCFed/  
AUCFasted 
CmaxFed/ 
CmaxFasted 
2017 Spironalactone Carospir® 
CAROSPIR can be taken with or without 
food, but should be taken consistently 
with respect to food 
Positive 1.9 - 
2017 Glecarprevir Pibrentasvir Mavyret® Take orally once daily with food Positive 
1.83-2.63a 
1.4-1.53a - 
2017 
Sofosbuvir 
Velpatasvir 
Voxilaprevir 
Vosevi® Taken orally once daily with food Positive 
1.64-2.44b 
1.4-2.66b 
2.12-5.35b 
- 
2017 Deutetrabenazine Austedo® Administer with food Positive 1c 1.5 
2017 Betrixaban Bevyxxa® Take at the same time each day with food Negative 0.39
d  
0.52e 
0.3d 
0.5e 
2017 Telotristat ethyl Xermelo® Take with food Positive 3.64
f 
1.33g 
2.12f 
1.47g 
2016 Tenofovir alafenamide Vemlidy® Take with food Positive 1.65 - 
2016 Cabozatinib Cabometyx® Take at least 2 hours before and at least one hour after food Positive 1.57 1.41 
2016 Elbasvir  Grazoprevir Zepatier® Taken with or without food 
Neutral; Elbasavir 0.89 0.85 
Positive; 
Grazoprevir 1.5 2.8 
2016 Migalastat hydrochloride Galafold® 
Take on an empty stomach, at least 2 
hours before or after food intake Negative 0.6 - 
2016 Dronabinol Syndros® 
Because food delays the absorption of 
SYNDROS, administer the first dose on an 
empty stomach at least 30 
minutes before eating. Subsequent doses 
can be taken without regard to meals. 
Positive 2.5 0.8 
2016 Emtricitabine Rilpivirine Odefsey® Take with a meal Positive 
Emtricitabine 
0.91h, 0.88e  - 
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Tenofovir alafenamide Rilpivirine 
1.13h, 1.72e 
Tenofovir 
alafenamide 
1.45h, 1.53e 
2016 Rucaparib Rubraca® Take with or without food Positive 1.38 1.2 
2016 Sofosbuvir  Velpatasvir Epclusa® Take with or without food 
Positive; 
sofosbuvir 
1.6h 
1.78e - 
Positive; 
velpatasvir 
1.21h 
1.34e - 
2016 Venetoclax Venclexta® Take with a meal and water Positive 3.4
d 
5.1e - 
2015 
Elvitegravir 
Cobicistat 
Emtricitbine 
Tenofovir alafenamide 
Genvoya® Take Once Daily with Food Positive 
Elvitegravir 
1.34d 
1.87e 
- 
2015 Alectinib Alecensa® Administer with food Positive 3.1 - 
2015 Daclatasvir Daklinza® With or without food, with sofosbuvir Negative 0.77 0.72 
2015 Eluxadoline Viberzi® Taken twice daily with food Negative 0.4 0.5 
2015 Flibanserin Addyi® No instructions with regard to food intake Positive 
1.18d 
1.43h 
1.56e 
1.02d 
1.13h 
1.15e 
2015 Idebenone Raxone® Administer with food Positive 5-7 - 
2015 Ivabradine Corlanor®/ Procoralan® Take with meals Positive 1.2-1.4 - 
2015 Ixazomib Ninlaro® Taken at least one hour before or 2 hours after food Negative 0.72 0.31 
2015 lumacaftor  ivacaftor Orkambi® Take with fat containing food 
Positve; 
Lumacaftor 2 - 
Positive; Ivacaftor 3 - 
2015 Palbociclib Ibrance® Take with food Positive 1.12
d 
1.13h 
1.27d 
1.24h 
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1.21e 1.38e 
2015 Sonidegib Odomzo® Take on an empty stomach Positive 7.4-7.8 7.4-7.8 
2015 Tasimelteon Hetlioz® Taken without food Negative - 0.56 
2015 Trifluridine  Tipiracil Lonsurf® 
Within One hour after completion of meal Negative 1c 0.6 
Take with food, as decrease in Trifluridine 
Cmax can prevent decrease in neutrophils 
Negative 0.6 0.6 
2014 Ceritinib Zykadia® 
Administer ZYKADIA on an empty stomach 
(i.e., do not administer within 2 hours of a 
meal) 
Positive 1.58
d 
1.73e 
1.43d 
1.41e 
2014 Delamanid Deltyba® Delamanid should be taken with food Positve 2.7 - 
2014 Droxidopa Northera® Take consistently with or without food Negative 0.8 0.65 
2014 Idelalisib Zydelig® Zydelig can be taken with or without food Positive 1.4 - 
2014 
Ledipasvir 
Harvoni® Taken daily with or without food 
None; ledipasvir 1c 1c 
Sofosbuvir Positive; sofosbuvir 2 1
c 
2014 Naloxegol Movantik® 
Take on an empty stomach at least 1 hour 
prior to the first meal of the day or 2 hours 
after the meal 
Positive 1.45 1.3 
2014 Nintedanib Ofev® Take with food Positive 1.2 - 
2014 Pirfenidone Esbriet® Three times daily taken with food. Negative 0.84 0.51 
2014 Suvorexant Belsomra® 
Suvorexant may be taken with or without 
food; however for faster sleep onset, 
suvorexant should not be administered 
with or soon after a meal 
None 1c 1c 
2014 Tasimelteon Hetlioz® Take without food Negative - 0.56 
2013 Afatinib Gilotrif® Take at least 1 hour before or 2 hours after a meal Negative 0.61 0.5 
2013 Dabrafenib Tafinlar® Taken at least 1 hour before or at least 2 hours after a meal Negative 0.69 0.49 
2013 Dimethyl fumarate Tecfidera® Take TECFIDERA with or without food Negative 1c 0.6 
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2013 Dolutegravir Tivicay® May be taken without regard to meals Positive 
1.33d 
1.41h 
1.66e 
1.46d 
1.52h 
1.67e 
2013 Obrutinib Imbruvica® No instructions with regard to food intake Positive 2 - 
2013 
Nalmefene 
hydrochloride 
dihydrate 
Selincro® Selincro can be taken with or without food Positive 1.3 1.5 
2013 Ospemifene Osphena® One tablet taken orally once daily with food Positive 1.7 2.3 
2013 Simeprevir Olysio® One 150 mg capsule taken once daily with food Positive 1.69
e  - 
2013 Trametinib Mekinist® Take at least 1 hour before or at least 2 hours after a meal Negative 0.76 0.3 
2012 Bedaquiline Sirturo® Bedaquiline should be taken with food to enhance its oral bioavailability Positive 2 - 
2012 Bosutinib Bosulif® Taken once daily with food. Positive 1.7 1.8 
2012 Cabozantinib Cometriq® 
Instruct patients not to eat for at least 2 
hours before and at least 1 hour after 
taking COMETRIQ. 
Positive 1.57 1.41 
2012 
Elvitegravir 
Stribild® The recommended dose of STRIBILD is one tablet taken orally once daily with food 
Positive 1.34
d  
1.87e - 
Cobicistat Neutral 1c - 
Emtricitabine Neutral 1c - 
Tenofovir disoproxil 
fumarate Positive 
1.24d 
1.23e - 
2012 Ivacaftor Kalydeco® Taken orally every 12 hours with fat-containing food Positive 2 to 4 - 
2012 Mirabegron Myrbetriq®/ Betmiga® Taken once daily with or without food Negative 
0.49d 
0.83e 
0.25d 
0.55e 
2012 Regorafenib Stivarga® Take Stivarga with food (a low-fat breakfast) Positive 
1.48e 
0.8e,g 
0.49e,g 
1.36d 
- 
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1.4d,g 
1.23d,g 
2012 Isotretinoin Absorica®/ Epuris® 
Recommended dosage of 0.5 to 1 
mg/kg/day given in two divided doses 
without regards to meals for 15 to 20 
weeks 
Positive 1.5 1.26 
2011 Abiraterone acetate Zytiga® ZYTIGA must be taken on an empty stomach Positive 
5d 
10e 
7d 
17e 
2011 Boceprevir Victrelis® 
800 mg administered orally three times 
daily (every 7 - 9 hours) with food (a meal 
or light snack). 
Positive 1.65 - 
2011 Gabapentin enacarbil Horizant® Once daily taken with food at about 5 PM Positive 
1.24d 
1.34h  
1.44e 
- 
2011 
Piperaquine 
tetraphosphate 
Artenimol 
Eurartesim® 
Eurartesim should be administered with 
water no less than 3 hours after the last 
food intake, and no food should be taken 
within 3 hours after each dose 
Positive 
Piperaquine;  
3 
Artenimol;  
1.43 
- 
2011 Rilpivirine hydrochloride Edurant® Taken once daily with a meal Positive 1.666667 - 
2011 Rivaroxaban Xarelto® 10mg and 15mg; With or without food 20mg; Take with food 
10mg and 15mg; 
Neutral 
20mg Positive 
1c (10mg) 
1.39 (20mg) - 
2011 Telaprevir Incivek® 
INCIVEK tablets is 750 mg (two 375-mg 
tablets) taken orally 3 times a day (7-9 
hours apart) with food (not low fat) 
Positive 
2.17d 
3.37h   
4.3e 
- 
2011 Vemurafenib Zelboraf® Take with or without a meal Positive 4.6-5.1 2.5 
2011 Vilazodone hydrochloride Viibryd® VIIBRYD should be taken with food. Positive 1.64 - 1.85 2.47 - 2.6 
2010 Dronedarone Multaq® Take twice a day with morning and evening meals Positive 3.75 - 
2010 Fampridine Fampyra® Since there is a clear relationship between Cmax and dose related adverse reactions, Positive 0.93-0.98 1.15-1.23 
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it is recommended to take Fampyra 
without food 
2010 Lurasidone HCl Latuda® Latuda should be taken with food Positive 2 3 
a Mean systemic exposures with moderate to high fat meals 395 
b Values refer to geometric mean systemic exposure. 396 
c Where no numerical values for food effect were obtained but no significant food effect was observed a value of 1 was assigned 397 
d Low fat fed 398 
e High fat fed 399 
f Parent compound 400 
g Active metabolite 401 
h Moderate fat meal 402 
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Strategies to overcome food effect bioavailability in drug development 404 
Where food effects are identified, there is generally three choices facing drug development and/or 405 
regulatory scientists: (1) consider an alternative lead drug molecule that will not display food effects, 406 
(2) apply specific instructions for how a medicine is taken with regard to food or (3) design a 407 
formulation which overcomes to food effect. With an increasing desire to improve R&D efficiency in 408 
drug development, and the ‘quick win, fast fail approach’ now favoured in drug development, there 409 
is an increasing desire to predict food effects earlier in the drug development process [105, 106]. This 410 
will also allow potential to identify a food-independent formulation, approaches to which are 411 
described here. The primary focus is on the clinical performance observed with such formulation 412 
approaches, while notable studies in preclinical studies, principally in beagle dogs are also reviewed. 413 
While pre-clinical animal models, including the dog model, are not always representative of human 414 
bioavailability, they remain a cornerstone of pre-clinical formulation development, particularly with 415 
regard to food effect [105, 107]. Dogs are indeed the most widely characterised animal model in food 416 
effect studies, and dog specific food effect models are widely available, with a general tendency to 417 
be over-predictive of human food effect [108, 109]. 418 
Lead candidate modification and optimisation 419 
Once a potential lead compound has been identified during the drug development process, the final 420 
drug discovery phase involves modifying the molecular structure or physicochemical properties of 421 
the potential drug candidate to improve biopharmaceutical performance. The two guiding principles 422 
are the maintenance of favourable properties in lead compounds, retaining the motifs identified as 423 
crucial to the structure activity ratio (SAR), while also improving deficiencies in drug structure, often 424 
with the aim of improving the deliverability of the drug [110]. While it is unlikely that development 425 
scientists will specifically focus on food effect at this stage, identification and selection of 426 
appropriate lead candidates can lead to a reduction in food effect bioavailability later in the 427 
development process. While studies focussing on modifying the structure and physiochemical 428 
properties of a lead candidates specifically with the aim of reducing the impact of food are sparse, 429 
there are numerous examples of marketed drugs with related chemical and clinical properties, but 430 
differing food effects.  431 
Pithavala et al. examined the effect that crystal habit may have on absorption and food-effect, and 432 
demonstrated the importance of screening drug polymorphs. Initial first in human (FIH) trials 433 
suggested a negative food effect for axitinib form IV in a film-coated, immediate release tablet. A 434 
23% reduction in absorption in the fed state was demonstrated. Subsequent investigations identified 435 
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a more stable polymorph, form XLI. Food effect studies carried out with form XLI demonstrated an 436 
increase in the overall bioavailability of 19% with a high fat meal, and a 10% reduction with a 437 
moderate fat meal compared to fasting, which were not considered to be clinically significant 438 
changes [111].  439 
Modifying the chemical structure by means of producing prodrugs can also be used to eliminate 440 
food effect, as demonstrated by the development of fosamprenavir, a prodrug of the previously 441 
marketed protease inhibitor amprenavir. Due to its poor solubility, amprenavir was originally 442 
formulated as a lipid based formulation (Agenerase®) which demonstrated reduced bioavailability 443 
(AUC decreased by 23%) when taken with a high fat meal. Fosamprenavir, a phosphate ester 444 
prodrug with improved solubility, was originally developed with a view to reduce the significant daily 445 
pill burden associated with Agenerase® (eight capsules, twice daily). Successful formulation of 446 
fosamprenavir (Telzir®) not only reduced the dosing schedule to one tablet twice daily, but also 447 
eliminated the negative food effect seen with amprenavir, allowing dosing independent of prandial 448 
state [112]. 449 
The prodrug approach has also been used to produce the gabapentin ester, gabapentin enacarbil. 450 
The original aim of such an approach was to increase the poor and saturable bioavailability of 451 
gabapentin. The ester prodrug is completely hydrolysed to gabapentin by esterase enzymes in the 452 
gut and liver [113, 114]. While gabapentin bioavailability is greater from the prodrug when dosed in 453 
equimolar concentrations, Horizant® (gabapentin enacarbil) is required to be dosed with a meal, 454 
while Neurontin® (gabapentin) can be dosed with or without food. Numerous studies have 455 
demonstrated increases in exposure to gabapentin after oral dosing as gabapentin enacarbil [113, 115, 456 
114]. Mean increases in AUCinf of 23% for low fat, 31% for moderate fat and 40% for high fat meals 457 
have been observed in one study  [115]. Meanwhile exposure to gabapentin from Neurontin® is not 458 
significantly different in the fasted and fed states with an increase of 14% in AUC and Cmax in the fed 459 
state [116]. Direct comparison in these cases is, however, difficult as gabapentin enacarbil is only 460 
utilised in extended release preparations, while gabapentin is an immediate release formulation and 461 
both compounds are utilised for different indications. A similar approach, using an ester prodrug, 462 
has also been demonstrated to improve the bioavailability and eliminate the food effect for the 463 
direct thrombin inhibitor melagatran [117]. 464 
Formulation approaches to enhance bioavailability 465 
Numerous formulation approaches have been utilised to overcome food effects on bioavailability 466 
and the type of formulation chosen will depend on the nature and mechanism of the food effect, the 467 
drugs physiochemical properties and the intended therapeutic profile. To date, the majority of 468 
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studies aimed at overcoming food effect have focused on poorly water soluble, BCS class II 469 
compounds. This is both due to these molecules being the most commonly observed class in drug 470 
development pipelines, and the fact that these molecules are the most amenable to formulation 471 
approaches designed to overcome their biopharmaceutical limitations. This has provided a focus for 472 
the development of bio-enabling formulations to improve dissolution and bioavailability, ultimately 473 
with the aim of ensuring BCS class II compounds will behave more like BCS class I compounds in vivo. 474 
It is widely stated that by maximising dissolution in vivo in the fasted state it may also be possible to 475 
prevent the postprandial increases in solubilisation and mitigate or eliminate a positive food effect 476 
entirely, though as we will discuss below, this may be an oversimplification. While each of the 477 
formulations discussed in this article have indeed been well characterised elsewhere, they are 478 
discussed here specifically in the context of their use in eliminating food effects on bioavailability. 479 
Nanosized preparations 480 
The term nanocrystal  has emerged to describe drug particles with a crystalline structure in the 481 
nanoscale range [118]. Nanosizing refers to the reduction of API particle size to the sub-micron range, 482 
typically <500nm, and with modern production techniques it is possible to achieve particle size in the 483 
100-200nm range [119]. The reduction in particle size leads to an increase in surface area available for 484 
solvation and increases the rate of dissolution. The formation of nanoparticles may not only enhance 485 
dissolution, but evidence exists that solubility may also be increased through changes in the particle 486 
curvature and introduction of defects into the crystal lattice, while the thickness of the diffusion 487 
layer surrounding the particle may also be reduced [120-122, 118]. Nanonisation of API has proven useful 488 
in enhancing the bioavailability of PWSD, and numerous commercial examples exist, and many of 489 
these commercial preparations have been shown to eliminate a positive food effect previously seen 490 
with marketed preparations or in the drug development process. 491 
Fenofibrate has been widely investigated as a model PWSD displaying positive food effect 492 
bioavailability. Originally marketed as a co-micronized capsule, with an API particle size of 5-15 µm, 493 
which required dosing with food to achieve maximal absorption of a 200mg dose, it has repeatedly 494 
been reformulated using different bio-enabling approaches. Two nanonized preparations of 495 
fenofibrate have so far reached market, namely Tricor® (also marketed as Lipantil® Supra; prepared 496 
using NanoCrystal® milling technique developed by Elan Nanosystems) and Triglide™ (prepared via 497 
high pressure homogenisation). Comparison of absorption from 145 mg nanosized Tricor® 498 
formulation in the fasted and fed state to that of the 160 mg microcoated tablets demonstrated 499 
similar exposure in the fed state, while absorption from the nanonized tablet was increased in the 500 
fasted state and resulted in the elimination of a food effect [123, 124]. 501 
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Aprepitant is a BCS class IV compound which was formulated as a nanoparticle, using NanoCrystal® 502 
technology, during drug development to enhance fasted state dissolution. The final preparation was 503 
marketed as EMEND® and was found to improve fasted state exposure and eliminate the positive 504 
food effect seen with early tablet formulations in clinical development [125, 126]. 505 
Megestrol acetate is a steroidal progestin which is licensed for use as an appetite stimulant in 506 
anorexia and cachexia. Thus, the positive food effect seen with the original Megace® oral 507 
suspension, along with the 800mg dose in the relatively large volume of 20 mL suspension was seen 508 
as problematic in patients with decreased appetite. Reformulation as the nanocrystalline Megace® 509 
ES demonstrated a reduction of food effect, but also allowed dose reduction to 625mg administered 510 
in 5 mL of the new formulation [127, 128].   511 
The advantages of nanonized API compared to other methods of particle size reduction, specifically 512 
micronization through hammer- or jet-milling was demonstrated by Jinno et al. [129]. Here, a spray 513 
dried nanocrystalline suspension of cilostazol not only improved bioavailability approximately 5 fold 514 
in fasted beagle dogs relative to two different micronized preparations, but also eliminated the 515 
positive food effect seen with the micronized formulations. This was attributed to improved 516 
dissolution, as demonstrated in biorelevant FaSSIF media [129]. 517 
Several other nanocrystalline preparations have also demonstrated enhanced fasted state 518 
bioavailability in the fasted state and elimination of food effect in pre-clinical animal models, 519 
including ziprasidone [91, 130], lurasidone [131] and the novel gamma secretase inhibitor ELND006 [132]. 520 
Table 4 contains numerous examples of commercially available nanocrystalline preparations where 521 
food effect has been studied. In all cases a significant food effect observed with previous 522 
formulations has been mitigated or eliminated, demonstrating that nanosizing is an effective 523 
approach to eliminating food effect bioavailability. 524 
Amorphisation and solid dispersion 525 
The term solid dispersion describes a wide range of different, but related formulations which are 526 
designed to maintain drug in an amorphous or phase-separated crystalline state [133]. By reducing the 527 
drug particle size to the molecular level rapid dissolution can be facilitated, and production of an 528 
amorphous form will improve the apparent solubility, while solid dispersion can also confer 529 
improved wettability, increased porosity and, ultimately, improved biopharmaceutical performance 530 
[134-136]. Solid dispersions are being used increasingly often as bio-enabling formulations for PWSD to 531 
enhance oral bioavailability and numerous commercial preparations exist [137]. These preparations 532 
most often exist as amorphous drug dispersed in an inert carrier matrix, and this narrow definition 533 
has been used to describe their behaviour [138].  534 
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One such example is that of Kaletra®, a combination product of lopinavir and ritonavir produced 535 
using solid dispersion technology, specifically hot melt extrusion, using PVP/VA as a carrier [139]. 536 
Having originally been formulated as a soft gelatin capsule containing lipid excipients, the capsule 537 
formulation of Kaletra® were required to be taken with food, with a 48% increase in bioavailability 538 
observed in the fed state. The poor solubility of the API also meant that the capsule dose was limited 539 
to an 80mg/20mg strength capsule. Reformulation as a solid dispersion allowed production of a 540 
200mg/50mg tablet, reducing the pill burden from 10 capsules daily to four tablets daily. The 541 
amorphous solid dispersion formulation also displayed only insignificant changes in bioavailbility in 542 
the fed compared to the fasted state, allowing food independent dosing [139].  543 
Similarly, Lynparza® (olaparib) has been reformulated from a lipid-based, crystalline solid dispersion 544 
of micronised olaparib in Gelucire®, to a hot-melt extrusion based dispersion using copovidone as a 545 
carrier [140]. While the original formulation was developed after significant pre-clinical development, 546 
and displayed a 2-fold increase relative to a standard immediate release tablet, relatively low drug 547 
loading (10%) led to a significant pill burden for patients (16 capsules daily) [141]. The development of 548 
the melt extrusion tablet formulation both increased olaparib bioavailability and drug loading, 549 
allowing a dose reduction from 400mg to 300mg twice daily, and reduced the pill burden to four 550 
tablets daily. The food effect was also reduced, with a 20% increase in exposure observed for the 551 
capsule compared to a 9% increase with the tablet formulation [142, 143, 140]. 552 
Banarjee et al. developed a ziprasidone solid dispersion via hot melt extrusion, which retained 553 
crystalline characteristics of ziprasidone while suspending the drug in a hydrophilic matrix to 554 
improve wettability and dissolution, resulting in a nearly 10-fold increase in solubility. The enhanced 555 
dissolution translated to improved bioavailability in fasted healthy volunteers, while simultaneously 556 
eliminating the positive food effect observed with the commercial Zeldox® formulation [144]. 557 
However, while these approaches have successfully reduced food effect using solid dispersion 558 
technology, table 4 contains numerous examples where this is not the case. For the marketed solid 559 
dispersion formulations and amorphous drug preparations for which food effect data could be found 560 
(n = 21) almost half (n = 10) display positive food effect, while four preparations displayed a negative 561 
food effect. The fact that two thirds of these bio-enabled formulations display food effect 562 
bioavailability suggests that while solid dispersions may well improve dissolution in the fasted state, 563 
quite often solubility limitations remain. 564 
Lipid Based Formulations 565 
The original rationale for the investigation of the use of lipid-based formulations (LBF) to increase 566 
bioavailability of PWSD was the observation of positive food effects for many of these compounds 567 
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[145]. The ability of food to enhance the absorption of PWSD has long been attributed to the ability of 568 
meal components, and in particular lipids, to enhance drug solubilisation, dissolution and 569 
absorption. Thus, the addition of exogenous lipids to pharmaceutical preparations was proposed and 570 
investigated as a viable option to enhance the bioavailability of PWSD. LBFs have thus become one 571 
the most widely investigated and characterised formulation types for bioavailability enhancement 572 
and the elimination of a positive food effect, and have become ‘renowned for their potential to 573 
reduce the impact of food on drug absorption [146]. One of the earliest studies to specifically focus on 574 
the utility of LBF to eliminate food effect bioavailability was that of Charman et al. (1993). This study 575 
demonstrated that the approximately 3 fold increase in Cmax and AUC observed for a commercial 576 
danazol capsule formulation (Danocrine®) was elimninated using a lipid emulsion of danazol in 577 
glycerol mono-oleate [147].  578 
However, eliminating food effect using LBF is not always straightforward, and can require significant 579 
formulation development, as is the case for lipid-based formulations of cyclosporine. The 580 
commercial success of self-emulsifying drug delivery system (SEDDS) formulation of Neoral® owing 581 
principally to its elimination of the food effects and reducing inter-subject variability relative to the  582 
crude lipid emulsion formulation of Sandimmune® [148, 149]. Delivery as a crude emulsion was not 583 
sufficient to overcome the food effect, which required a more elaborate SEDDS formulation. 584 
Similarly, Roaccutane® is a soft gelatin capsule, which contains isotretinoin solubilised in water-585 
insoluble solvents, namely beeswax, soya bean oil and hydrogenated soya bean oil, which displays 586 
an approximately 2.7 fold increase in bioavailbility in the fed compared to fasted state. Absorica® is a 587 
novel isotretinoin formulation developed using Lidose® technology, which enhanced the fasting 588 
state bioavailbility and reduced the food effect to a 1.5 fold increase, which is not considered to be 589 
clinically significant and allows food independent dosing [150]. 590 
While the use of LBF to eliminate food effect has been widely acknowledged, it is interesting to look 591 
more critically at this claim. The use of LBF to enhance the fasted state bioavailability has been the 592 
major focus of formulation development over the last five decades, and it is a logical inference that 593 
by enhancing the solubility limited bioavailability in the fasted state, the post-prandial increase in 594 
absorption mediated by increased solubility can be reduced or avoided. However, as presented in 595 
table 4, of the 29 LBFs for which food effect data was gathered, 17 of these formulations displayed 596 
significant positive food effect, while only 9 formulations demonstrating truly food independent 597 
dosing.  598 
This can be exemplified by the case study of Fortovase®, a SEDDS formulation designed to improve 599 
the oral bioavailability of saquinavir, relative to the conventional capsule formulation, Invirase®. 600 
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While bioavailability was enhanced approximately three fold by Fortovase®, a significant food effect 601 
was still evident, with a similar increase in the fed state to that observed with Invirase® (6.7 fold 602 
increase). 603 
Perlman et al. have examined the food effect of torcetrapib in dogs using a range of different SEDDS 604 
formulations, finding that the composition of the formulation can be crucial in determining the food 605 
effect, with a food effect ranging from complete absence to 3.8 fold increase in beagle dogs. It 606 
should be noted, however, that all formulations reduced the food effect seen with aqueous (18 fold 607 
increase) and lipid (5 fold increase) suspensions used in early drug development [151]. Thus, while 608 
simply administering PWSD with lipids may reduce the magnitude of the food effect, true 609 
elimination may require more extensive formulation optimisation [8]. Christiansen et al. have 610 
similarly demonstrated a reduction of food effect for cinnarizine tablets when co-administered with 611 
placebo SNEDDS, relative to administration without this placebo lipid formulation in healthy 612 
volunteers, though complete elimination of food effect was not possible [152]. 613 
Various other lipid-based formulations have also been investigated in pre-clinical species with 614 
varying levels of success, and with a general trend towards reducing rather than eliminating food 615 
effects [153-163]. While the assertion that LBF are excellent candidates to eliminate food effect is 616 
widespread, the evidence from the literature, and from product literature in particular is 617 
underwhelming and a more systematic investigations are required to fully elucidate the potential for 618 
LBF to overcome food effects [164].  619 
Cyclodextrins 620 
Cyclodextrins have been widely used to enhance the oral bioavailability of lipophilic and poorly 621 
water-soluble drugs, in both pre-clinical animals and in humans. The bioavailability enhancing effects 622 
are mainly due to enhanced dissolution kinetics, increased solubility and potential reduction in 623 
degradation as well as increased permeability [165].  Experience with cyclodextrins with a specific 624 
focus on elimination of food effect is, however, limited. 625 
Sporanox® (itraconazole) has been formulated both as an amorphous solid dispersion, which 626 
displayed significant, positive food effect and as an oral solution solubilised by hydroxypropyl-β-627 
cyclodextrin inclusion complex. Sporanox® cyclodextrin solution has demonstrated higher 628 
bioavailability than Sporanox capsules in the fed state, and has also been demonstrated to show 629 
enhanced bioavailbility in the fasted state, eliminating the need for fed state dosing [166-168].  630 
Along with the commercial itraconazole preparataion, cyclodextrin complexes have also been 631 
investigated in pre-clinical food effect studies. Thombre et al. have demonstrated that a sulfobutyl 632 
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ether- β-cyclodextrin (SBE-β-CD) inclusion complex enhanced fasted bioavailability and eliminated 633 
food effect for ziprasidone relative to the commercial preparation (Geodon®) in beagle dogs [91, 169]. 634 
Wang et al. have recently demonstrated similar results with an SBE-β-CD complex of amiodarone 635 
[170]. 636 
While the experience with cyclodextrin preparations for eliminating food effect is limited, these 637 
examples show promise for this formulation method to eliminate food effect, though overall clinical 638 
acceptability may be limited as the relatively large intake volume (up to 20 mL for Sporanox® 639 
solution) may be problematic for some patients. 640 
  641 
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Guiding formulation selection 642 
With the range of formulations available, identification of the biopharmaceutical risks for a 643 
particular drug candidate is essential in order to ensure the most appropriate formulation is chosen. 644 
While it may be possible that different types of formulation may achieve improved solubilisation for 645 
a particular drug candidate, identification of the most beneficial formulation can be advantageous in 646 
the industrial setting where developing parallel formulation portfolios can put a strain on the limited 647 
timelines and resources. Kuentz et al. have recently reviewed the various methods by which 648 
formulations are selected in the pharmaceutical industry [171]. The key elements of formulation 649 
screening involve identifying the critical physiochemical and biopharmaceutical properties that are 650 
likely to play a role in drug bioavailability and generating a target product profile (TPP). Ideally, 651 
formulation decision trees based on a basic set of drug properties, such as that proposed by 652 
Rabinow et al. [172], or those based on identifying the biopharmaceutical limitations, such as the BCS 653 
based decision trees suggested by Ku et al. [173], can be implemented and will provide a relative 654 
simple strategy to formulation choice. There is an abundance of such decision trees in the literature, 655 
with focus on enhancing bioavailability and manufacturability of drug candidates. However, given 656 
the lack of a clear consensus on the appropriate prediction of food effect bioavailability and the 657 
contradictory evidence of the various formulation options at eliminating food effect, it is no surprise 658 
that no decision tree exists specifically focus on eliminating the food effect. In the absence of a 659 
specific decision tree, choice is best guided by analysing BCS/BDDCS class assignment and utilisation 660 
of existing decision trees for each appropriate class. Formulation approaches suitable for each class 661 
are summarised in figure 4. 662 
While significant experience, no doubt, exists within the pharmaceutical industry, this data is often 663 
not published in the literature. The paucity of data regarding the systematic and structured 664 
development of formulations with the intention of eliminating food effect means that, initially, the 665 
decision to focus on one particular formulation approach to eliminate a food effect remains largely 666 
empiric. More thorough formulation development and characterisation, however, can benefit from a 667 
more mechanistic approach, using a range of in vitro, in vivo and in silico tools. A recent example of 668 
such an approach is that of Pandey et al. [174]. In this work, the group first identified a large food 669 
effect in an early stage clinical trial in healthy volunteers. This food effect was subsequently 670 
investigated mechanistically using biorelevant in vitro screening tools along with in silico modelling 671 
using the GastroPlus® ACAT model. This biorelevant screening identified that the key mechanism 672 
governing the observed positive food effect was the enhanced solubilisation by dietary lipids, while 673 
in silico modelling suggested that other contributory factors were involved, including the changing 674 
pH and the impact of gastrointestinal transporters and metabolism. The integration of the early 675 
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clinical data with the biorelevant measurements with the in silico model allowed development of a 676 
bio-predictive in vitro dissolution method, which enabled rapid formulation screening. Formulation 677 
screening led to the development of a surfactant containing, wet-granulated tablet formulation. The 678 
approximately 3.5-fold increase in fed state bioavailability observed for the dry granulated 679 
formulation was reduced to an approximately 1.5-fold increase, which was deemed not to be 680 
clinically significant for this compound [174]. 681 
 682 
Figure 4 Approaches to formulation design based on BCS/BDDCS classification  683 
  684 
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Table 3 Approved bio-enabling formulations with clinical food effect data 685 
Data obtained from FDA Drug Label (from Drugs@FDA database) or European Summary of Pharmaceutical 686 
Characteristics (SPC) unless otherwise stated 687 
  Trade name API Clinical recommendation AUCF   
Am
po
rh
ou
s s
ol
id
 d
isp
er
sio
ns
 
Cesamet® Nabilone No specific instructions   
Sporanox® 
(capsule)/ 
Onmel® 
Itraconazole 
Sporanox is for oral administration and must be 
taken immediately after a meal for maximal 
absorption. 
   
Prograf® Tacrolimus Administer capsules consistently with or without food   
Kaletra® Ritonaivr/lopinavir Kaletra tablets can be taken with or without food. 
 
 
 
 
Intelence® Etravirine Taken following a meal   
Zortress®/ 
Certican® Everolimus 
Administer consistently with or without food  at 
the same time as cyclosporine.   
Norvir® Ritonavir Take Norvir with meals 
 
 
 
 
Zelboraf® Vemurafenib Administer ZELBORAF approximately 12 hours apart with or without a meal 4   
Incivek® Telaprevir Take with food (not low fat) 
 
 
 
 
Kalydeco® Ivacaftor With fat containing food       
Viekirax® 
Ombitasvir 
Viekirax tablets should be taken with food, without 
regard to fat and calorie content 
  
Paritaprevir   
Ritonavir   
Fenoglide® Fenofibrate Should be taken with meals   
Rezulin® Troglitazone Rezulin should be taken with a meal 1.3     
Noxafil® Posaconazole Taken with food   
Pu
re
 
Am
or
ph
ou
s 
Dr
ug
 
Ceftin® Cefuroxime axetil Administer tablets with or without food   
Viracept® Nelfinavir mesylate VIRACEPT should be taken with a meal 
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Accupril® Quinapril HCl No specific instructions   
Victrelis® boceprevir Take three times daily with food (a meal or light snack)   
Crestor® Rosuvastatin Calcium 
CRESTOR can be administered as a single dose at 
any time of day, with or without food   
Zepatier® 
elbasavir One tablet taken orally once daily with or without 
food 
  
grazoprevir   
Accolate® Zafirlukast ACCOLATE should be taken at least 1 hour before or 2 hours after meals.   
Lip
id
 B
as
ed
 F
or
m
ul
at
io
ns
 
Agenerase® Amprenavir 
AGENERASE may be taken with or without food, 
however, a high fat meal decreases the absorption 
of amprenavir and should be avoided 
  
Neoral® Cyclosporin A/I Neoral be administered on a consistent schedule with regard to time of day and relation to meals.    
Accutane®/ 
Roaccutane® Isotretinoin Accutane should be administered with a meal   
Kaletra® 
Lopinavir  
Ritonavir 
Kaletra capsules must be taken with food 
 
 
 
 
Norvir® Ritonavir Take with food   
Restandol®/ 
Andriol® 
Testocaps 
Testosterone 
undecanoate 
Restandol Testocaps must be taken with a normal 
meal   
Targretin® Bexarotene Targretin® capsules should be taken as a single oral daily dose with a meal.   
Lamprene® Clofazimine Administer 100 mg LAMPRENE daily with meals 
1  
1  
 
Sandimmune® Cyclosporin A To be administered on a consistent schedule with regard to time of day and relation to meals. 1   
Marinol® Dronabinol Take twice daily , before lunch and supper   
Avodart® Dutasteride May be administered with or without food     
Procardia® Nifedipine No specific instructions  
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Rapamune® Sirolimus Oral solution; Administer once daily by mouth, consistently with or without food   
Fortovase® Saquinavir FORTOVASE should be taken within 2 hours after a full meal   
Amitiza® Lubiprostone Take with food to reduce nausea   
Aptivus® Tipranavir Always take APTIVUS with food.   
Hycamtin® Topotecan HCl May be administered with or without food   
Akynzeo® 
Netupitant 
Can be taken with or without food 
 
  
Palonsetron   
Prometrium® Progesterone No specific instructions 
 
 
  
 
 
 
Utrogestan® Progesterone Utrogestan 100mg Capsules should not be taken with food and should be taken at bedtime.   
Absorica® Isotretinoin 
Recommended dosage of 0.5 to 1 mg/kg/day given 
in two divided doses without regards to meals for 
15 to 20 weeks 
  
Lipofen® Fenofibrate 
LIPOFEN™ capsules should be given with meals, 
thereby optimizing the absorption of the 
medication. 
 
 
 
Ofev® Nintedanib Take with food   
Navelbine® vinorlebine tartrate 
Administer the capsule with some food, as this has 
also been shown to reduce the incidence of nausea 
and vomiting 
  
Zemplar® Paricalcitol Without regard to meals   
Toctino® Alitretinoin With a main meal   
Vyndaqel® Tafamidis meglumine With or without food   
Rayaldee® calcifediol Once Daily at bedtime   
Xtandi® Enzalutamide XTANDI can be taken with or without food 
 
 
 
 
Na
no
cr
ys
ta
l 
Lipantil Supra® Fenofibrate Without regard to meals   
Megace® ES megestrol acetate No specific instructions   
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Emend® aprepitant With or without food   
Triglide® Fenofibrate TRIGLIDE may be administered with or without food   
Rapamune® sirolimus To minimise variability, Rapamune should consistently be taken either with or without food   
Cy
clo
de
xt
rin
 
Sporanox®  
(Oral solution) Itraconazole 
Oral solution; Taking SPORANOX® Oral Solution 
under fasted conditions improves the systemic 
availability of itraconazole. Instruct patients to 
take SPORANOX® Oral Solution 
without food, if possible 
 
 
 
  
Cr
ys
ta
lli
ne
 S
ol
id
 D
isp
er
sio
n 
Lynparza® 
(capsule) 
Olaparib micronised 
in Gelucire; 
manufactured as a 
suspension of drug 
in molten excipient 
No specific instructions   
Lynparza® 
(tablet) 
Hot melt extruded 
olaparib in co-
povidone carrier 
matrix 
Taken orally twice daily with or without food   
a Where no numerical values for food effect were obtained but no significant food effect was 688 
observed a value of 1 was assigned 689 
b Moderate fat meal 690 
c High fat meal 691 
d Low fat meal 692 
e With Breakfast 693 
f2 hours post breakfast 694 
g 4 hours post breakfast 695 
h Active metabolite696 
Conclusion 697 
This review has investigated the causes and impact of food mediated changes in drug bioavailability. 698 
While our mechanistic understanding of the causes of food effects, and our ability to predict when 699 
and why it might occur have developed significantly since Welling first reviewed this topic 40 years 700 
ago, food effects still pose significant problems with regard to both development and regulatory 701 
scientists. 702 
Despite the increased awareness of the negative clinical impact of food effects on bioavailability and 703 
the strict regulatory guidance regarding the appropriate testing of new medicinal products in the fed 704 
and fasted states there appears to be an ever-increasing challenge of food mediated alterations in 705 
drug bioavailability, likely reflecting the increasing prevalence of PWSD in drug development 706 
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pipelines. While there has been increasing understanding and development of improved drug 707 
delivery technologies, there remains an overall lack of appreciation of the scale of the food effect 708 
challenge, as evidenced by the fact that over 40% of new medicines display significant food effects, 709 
or possess a label claim in respect of dosing with regard to food intake.  This has had a knock-on 710 
effect in the clinic, where the success or commercial advantage of compounds can be affected, 711 
particularly with antipsychotic and oncological preparations. 712 
While this review has summarised the various formulation approaches that have been utilised to 713 
mitigate food effect, it is still difficult to definitively suggest a method of choice for formulating new 714 
compounds to overcome significant food effects. The major focus of formulation approaches to 715 
mitigate food effects to date has focused on compounds displaying positive food effects mediated 716 
by poor dissolution or solubility, while relatively limited approaches exist for drugs displaying 717 
negative food effects, where permeability, diffusivity or metabolism related limitations occur. It is 718 
interesting to note that despite significant improvements in formulation design and characterisation 719 
with regard to supersaturable and bioenabling formulations that many of these marketed 720 
formulations still appear to behave sub-optimally in vivo, specifically with regard to food effects.  721 
Formulating compounds to overcome food effect remains largely empirically driven, with only 722 
sporadic case studies for individual compounds published. While the presence or absence of food 723 
effects is unlikely to be a key driving factor in early formulation development, it can be a critical 724 
factor when entering the clinic. In the absence of large databanks of formulation design studies in 725 
easily obtainable literature, greater use of mechanistic and in silico approaches will be central to 726 
enhancing our ability to discriminate between formulations likely to overcome food-mediated 727 
alterations in drug bioavailability.   728 
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